Data / Drug companies / Aurohealth LLC
Aurohealth LLC: 179 products in the FDA NDC directory, labeler code 58602
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Aurohealth LLC (labeler code 58602) lists 179 products in the FDA National Drug Code Directory, covering 44 finished drugs by generic name. By type: 179 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 28, 2026.
The request: Watch Aurohealth LLC (FDA labeler code 58602): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 58602
- Products in commercial distribution
- 179
- Packages
- 786
- Finished drugs by generic name
- 44
- Prescription products
- 0
- Over the counter products
- 179
- Flagged as original packager
- 167 of 167 products that carry the flag
- Started marketing in the last 12 months
- 26
- Earliest marketing start
- February 2, 2010
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 154 | 86% |
| Over the counter monograph drugs | 25 | 14% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 179 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 38 | 21.2% |
| Tablet, extended release | 21 | 11.7% |
| Tablet, film coated | 19 | 10.6% |
| Suspension | 15 | 8.4% |
| Capsule | 12 | 6.7% |
| Solution | 11 | 6.1% |
| Lozenge | 10 | 5.6% |
| Tablet, orally disintegrating | 8 | 4.5% |
| Capsule, liquid filled | 7 | 3.9% |
| Spray, metered | 6 | 3.4% |
| Capsule, delayed release | 6 | 3.4% |
| Aerosol, foam | 4 | 2.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Ibuprofen | 58602-913 | Tablet | Generic drugs (ANDA) | September 28, 2026 |
| Polyethylene Glycol 3350 | 58602-910 | Powder, for solution | Generic drugs (ANDA) | September 28, 2026 |
| Minoxidil 5% (for men) | 58602-614 | Aerosol, foam | Generic drugs (ANDA) | September 25, 2026 |
| Omeprazole and sodium bicarbonate | 58602-732 | Capsule | Generic drugs (ANDA) | September 22, 2026 |
| Fexofenadine hydrochloride | 58602-427 | Suspension | Generic drugs (ANDA) | August 31, 2026 |
| Childrens triamcinolone acetonide | 58602-037 | Spray, metered | Generic drugs (ANDA) | August 11, 2026 |
| Triamcinolone acetonide | 58602-035 | Spray, metered | Generic drugs (ANDA) | August 11, 2026 |
| Childrens Pain and Fever | 58602-171 | Suspension | Over the counter monograph drugs | July 30, 2026 |
| Childrens Pain and Fever | 58602-164 | Suspension | Over the counter monograph drugs | July 30, 2026 |
| Childrens Pain and Fever | 58602-167 | Suspension | Over the counter monograph drugs | July 27, 2026 |
| Childrens Pain and Fever | 58602-166 | Suspension | Over the counter monograph drugs | July 23, 2026 |
| Childrens Pain and Fever | 58602-165 | Suspension | Over the counter monograph drugs | July 23, 2026 |
| Guaifenesin | 58602-857 | Tablet, extended release | Generic drugs (ANDA) | July 3, 2026 |
| Minoxidil 5% (for women) | 58602-104 | Aerosol, foam | Generic drugs (ANDA) | June 19, 2026 |
| Acetaminophen Regular Strength | 58602-748 | Tablet | Over the counter monograph drugs | June 8, 2026 |
| Infants Pain and Fever | 58602-173 | Suspension | Over the counter monograph drugs | May 18, 2026 |
| INFANTS Pain and Fever | 58602-172 | Suspension | Over the counter monograph drugs | May 18, 2026 |
| Dextromethorphan polistirex | 58602-618 | Suspension, extended release | Generic drugs (ANDA) | April 17, 2026 |
| Dextromethorphan polistirex | 58602-617 | Suspension, extended release | Generic drugs (ANDA) | April 17, 2026 |
| Dextromethorphan polistirex | 58602-611 | Suspension, extended release | Generic drugs (ANDA) | April 15, 2026 |
| Dextromethorphan polistirex | 58602-610 | Suspension, extended release | Generic drugs (ANDA) | April 15, 2026 |
| Infants Pain and Fever | 58602-169 | Suspension | Over the counter monograph drugs | March 20, 2026 |
| INFANTS Pain and Fever | 58602-168 | Suspension | Over the counter monograph drugs | March 20, 2026 |
| Pseudoephedrine Hydrochloride | 58602-884 | Tablet, extended release | Generic drugs (ANDA) | December 29, 2025 |
| Loperamide hydrochloride | 58602-727 | Capsule, liquid filled | Generic drugs (ANDA) | December 29, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.